Compare GSK plc (GSK) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marathon Petroleum Corp — how do they compare? GSK plc trades at $52.79 (market cap $101.34B), while Marathon Petroleum Corp trades at $305.9 (market cap $87.34B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MPC | |
|---|---|---|
Market Cap | $101.34B | $87.34B |
Sector | Health | Energy |
52-Week High | $61.18 | $303.40 |
52-Week Low | $36.20 | $158.59 |
Enterprise Value | $121.95B | $119.52B |
Dividend Yield | 3.49% | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Marathon Petroleum (MPC) trades at $303.40, up 2.2% on the day and near its recent highs, supported by strong technical momentum and bullish analyst sentiment. The stock demonstrates robust profitability with a 27.92% ROE and 3.42% net margin, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Recent news highlights the company's advantage from elevated refining margins and strategic upgrades, while a pending class-action lawsuit regarding AI price-fixing in California presents a notable risk.
The outlook is positive, driven by sustained high refining crack spreads and strategic positioning, with a consensus analyst price target of $292.70. Key risks include potential legal liabilities from the California lawsuit, volatile energy markets, and execution risks in maintaining profitability amid fluctuating crude costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
